| Will biomarkers be the answer for antibiotic stewardship? | Lancet Respiratory Medicine | 7 days | save |  |  |  |  |
| Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation | Lancet Respiratory Medicine | 7 days | save | | | | |
| Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial | Lancet Respiratory Medicine | 8 days | save | | | | |
| Active management of mild obstructive sleep apnoea: the evidence grows | Lancet Respiratory Medicine | 8 days | save | | | | |
| Life after tuberculosis: planning for health | Lancet Respiratory Medicine | 14 days | save | | | | |
| Familial lung disease presenting in reverse | Lancet Respiratory Medicine | 14 days | save | | | | |
| Life-threatening bronchiolitis in children: eight decades of critical care | Lancet Respiratory Medicine | 22 days | save | | | | |
| Correction to Lancet Respir Med 2019; published online Nov 6. https://doi.org/10.1016/S2213-2600(19)30418-7 | Lancet Respiratory Medicine | 24 days | save | | | | |
| American Thoracic Society calls for more research into military deployment respiratory exposures | Lancet Respiratory Medicine | 24 days | save | | | | |
| US States confront oil and gas drilling health hazards | Lancet Respiratory Medicine | 25 days | save | | | | |
| Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? | Lancet Respiratory Medicine | 28 days | save | | | | |
| Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial | Lancet Respiratory Medicine | 28 days | save | | | | |
| Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study | Lancet Respiratory Medicine | 29 days | save | | | | |
| Austria bans smoking in bars and restaurants | Lancet Respiratory Medicine | 29 days | save | | | | |
| Microbiological outliers in cystic fibrosis: resolving uncertainty | Lancet Respiratory Medicine | 29 days | save | | | | |
| E-cigarette regulation: getting it wrong costs lives | Lancet Respiratory Medicine | 31 days | save | | | | |
| E-cigarettes: banning flavours is better than an outright ban | Lancet Respiratory Medicine | 31 days | save | | | | |
| E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach | Lancet Respiratory Medicine | 31 days | save | | | | |
| Understanding and improving quality of care in preschool wheeze | Lancet Respiratory Medicine | 33 days | save | | | | |
| WHO global progress report on tuberculosis elimination | Lancet Respiratory Medicine | 34 days | save | | | | |
| The Cave | Lancet Respiratory Medicine | 34 days | save | | | | |
| Non-eosinophilic severe exacerbations of COPD: what about antibiotics? – Authors' reply | Lancet Respiratory Medicine | 34 days | save | | | | |
| Non-eosinophilic severe exacerbations of COPD: what about antibiotics? | Lancet Respiratory Medicine | 40 days | save | | | | |
| RISE-IIP: some pitfalls and observations | Lancet Respiratory Medicine | 48 days | save | | | | |
| Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial | Lancet Respiratory Medicine | 49 days | save | | | | |
| Early-life exposure to electronic cigarettes: cause for concern | Lancet Respiratory Medicine | 49 days | save | | | | |
| Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial | Lancet Respiratory Medicine | 49 days | save | | | | |
| Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial | Lancet Respiratory Medicine | 49 days | save | | | | |
| Pneumonia research: time to fill in the gaps | Lancet Respiratory Medicine | 54 days | save | | | | |
| Pulse oximetry in paediatric primary care in low-income and middle-income countries | Lancet Respiratory Medicine | 54 days | save | | | | |
| E-cigarette use in Great Britain | Lancet Respiratory Medicine | 54 days | save | | | | |
| Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities | Lancet Respiratory Medicine | 54 days | save | | | | |
| Pulmonary embolism in Europe remains a cause of concern despite declining deaths | Lancet Respiratory Medicine | 54 days | save | | | | |
| Next-generation ALK inhibitors: is the median the message? | Lancet Respiratory Medicine | 56 days | save | | | | |
| Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial | Lancet Respiratory Medicine | 56 days | save | | | | |
| Primary ciliary dyskinesia in the genomics age | Lancet Respiratory Medicine | 57 days | save | | | | |
| Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database | Lancet Respiratory Medicine | 59 days | save | | | | |
| India launches tuberculosis prevalence survey | Lancet Respiratory Medicine | 61 days | save | | | | |
| 2019 European Respiratory Society International Congress | Lancet Respiratory Medicine | 61 days | save | | | | |
| Breakthrough in the treatment of drug-resistant tuberculosis | Lancet Respiratory Medicine | 61 days | save | | | | |
| Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study | Lancet Respiratory Medicine | 62 days | save | | | | |
| Towards improved delivery of care in the paediatric ICU | Lancet Respiratory Medicine | 62 days | save | | | | |
| Vaping-induced severe respiratory disease outbreak: what went wrong? | Lancet Respiratory Medicine | 62 days | save | | | | |
| Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial | Lancet Respiratory Medicine | 62 days | save | | | | |
| The long-lasting dark shadow of past and present smoking | Lancet Respiratory Medicine | 62 days | save | | | | |
| Is ex-vivo viral eradication possible? | Lancet Respiratory Medicine | 62 days | save | | | | |
| Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group | Lancet Respiratory Medicine | 67 days | save | | | | |
| Secondary re-analysis of the FEAST trial | Lancet Respiratory Medicine | 73 days | save | | | | |
| Harnessing the microbiome for lung health | Lancet Respiratory Medicine | 74 days | save | | | | |
| IASLC 2019 World Conference on Lung Cancer | Lancet Respiratory Medicine | 81 days | save | | | | |
| | 
report | next » |
| |
